Ignite Creation Date:
2024-05-06 @ 12:58 AM
Last Modification Date:
2024-10-26 @ 10:57 AM
Study NCT ID:
NCT01700192
Status:
COMPLETED
Last Update Posted:
2017-09-15
First Post:
2012-10-02
Brief Title:
Efficacy and Safety Study of SCH 900237MK-8237 in Children and Adults With House Dust Mite-Induced Allergic RhinitisRhinoconjunctivitis P05607
Sponsor:
ALK-Abelló AS
Organization:
ALK-Abelló AS
Study Overview
Official Title:
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet SCH 900237MK 8237 in Children and Adult Subjects With House Dust Mite-Induced Allergic RhinitisRhinoconjunctivitis With or Without Asthma Protocol No P05607001
Status:
COMPLETED
Status Verified Date:
2017-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess the efficacy and safety of MK-8237 SCH 900237 in the treatment of House Dust Mite HDM-Induced Allergic RhinitisRhinoconjunctivitis ARARC in children and adults
The primary hypothesis of this study is that administration of MK-8237 compared to placebo results in significant reduction in the average total combined rhinitis score TCRS
The primary hypothesis of this study is that administration of MK-8237 compared to placebo results in significant reduction in the average total combined rhinitis score TCRS
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| MK-8237-001 | OTHER | Merck Protocol ID | None |